VERAXA Biotech AG (NASDAQ: VRXA) today announced new in vitro proof-of-concept data supporting its novel BiTAC(TM)-ADC technology platform, which is designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.
The findings further validate the potential of the BiTAC-ADC platform and complement VERAXA's BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026. According to the press release, the full details can be accessed at https://ibn.fm/QiPhH.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
The BiTAC-ADC platform addresses a key challenge in cancer therapy: achieving potent anti-tumor activity while sparing healthy tissues. By using two separately delivered precursor components that only assemble into an active drug within the tumor microenvironment, the approach aims to limit systemic toxicity. The in vitro data showed that BiTAC-ADCs selectively killed breast cancer cells in 3D spheroid models, which better mimic the tumor architecture than traditional 2D cultures. This suggests the platform may be effective against solid tumors, which are often difficult to treat with conventional ADCs due to poor penetration and off-target effects.
The announcement is significant as it provides VERAXA with a second proprietary technology platform alongside its BiTAC-TCE bispecific T cell engager platform. Having two distinct modalities targeting solid tumors could enhance the company's appeal to potential partners. The upcoming BIO International Convention presents an opportunity for management to engage with pharmaceutical companies interested in licensing or co-developing these technologies. Investors can find the latest news and updates relating to VRXA in the company's newsroom at http://ibn.fm/VRXA.
